@oriro/orirocli 0.1.9 → 0.1.11

package/skills/industry/industry-media/SKILL.md

@@ -1,66 +1,66 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-media
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-
-
-
-  Media and entertainment — content production, distribution, rights, monetization, streaming, and digital media.
-
-
-
-
-
-
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Media and Entertainment
-
-## Industry structure
-
-**Content creation:** Studios (film/TV), record labels (music), publishers (books/news), game developers, independent creators.
-**Distribution:** Streaming platforms (Netflix, Spotify, YouTube), broadcasters, cable systems, cinemas, retail.
-**Technology:** CDN, DRM, recommendation algorithms, ad tech, measurement.
-**Rights management:** Music licensing (ASCAP, BMI, SESAC for performance; Harry Fox/MRI for mechanical), film rights, publishing rights.
-
-## Rights and licensing
-
-### Music rights
-
-Every song has TWO copyrights:
-**Master recording:** Owned by recording artist/record label. Needed to use the actual recording.
-**Musical composition (publishing rights):** Owned by songwriter/publisher. Needed to use the song.
-Using music in film, TV, or commercial requires both licenses.
-
-**Performance rights:** Bars, venues, radio play require license from PROs (ASCAP, BMI, SESAC).
-**Sync license:** Use music in video content (film, TV, ads, games). Negotiated directly with rights holder.
-**Mechanical license:** Reproduce/distribute a song. Compulsory license available at statutory rate in US.
-
-### Film/TV rights
-
-**Option:** Pay to hold rights to a story/script for a period (often 12-18 months) before committing to purchase.
-**Chain of title:** Documented trail of all ownership and license agreements. Essential for financing and distribution.
-**Errors and Omissions (E&O) insurance:** Required by distributors. Protects against copyright, trademark, privacy claims.
-
-## Streaming economics
-
-**Netflix-style SVOD:** Monthly subscriber fee. Content cost = fixed. Marginal viewer = near zero cost.
-**Ad-supported streaming (AVOD):** Free to user; revenue from ads. CPM-based.
-**Transactional (TVOD):** Pay per view/purchase. Digital stores (iTunes, Amazon Prime Video).
-**Window strategy:** Theatrical → PVOD → SVOD/AVOD → linear TV. Windows compressed as streaming dominates.
-
-**Revenue waterfall (film):**
-Box office → Distributor takes 40-50% → Marketing and distribution costs recouped → Participations and residuals → Net profit (often illusory due to creative accounting).
-
-## Digital media and creator economy
-
-**Monetization models:** Ad revenue (CPM/RPM), brand sponsorships, subscriptions (Patreon, Substack), merchandise, events, licensing.
-**YouTube revenue share:** ~55% to creator, 45% to YouTube. $2-10 RPM typical ($2-10 per 1,000 views).
-**Spotify:** ~$0.003-0.005 per stream. 1 million streams ≈ $3,000-5,000.
-**Music on social media:** TikTok, Instagram, YouTube — blanket licenses with labels. Creator doesn't directly earn from music use.
-
-Sources: RIAA (riaa.com — free data), MPAA (motionpictures.org — free), Billboard (billboard.com/free content), Variety/Hollywood Reporter industry news (limited free), Music Business Worldwide (free)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-media
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+
+
+
+  Media and entertainment — content production, distribution, rights, monetization, streaming, and digital media.
+
+
+
+
+
+
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Media and Entertainment
+
+## Industry structure
+
+**Content creation:** Studios (film/TV), record labels (music), publishers (books/news), game developers, independent creators.
+**Distribution:** Streaming platforms (Netflix, Spotify, YouTube), broadcasters, cable systems, cinemas, retail.
+**Technology:** CDN, DRM, recommendation algorithms, ad tech, measurement.
+**Rights management:** Music licensing (ASCAP, BMI, SESAC for performance; Harry Fox/MRI for mechanical), film rights, publishing rights.
+
+## Rights and licensing
+
+### Music rights
+
+Every song has TWO copyrights:
+**Master recording:** Owned by recording artist/record label. Needed to use the actual recording.
+**Musical composition (publishing rights):** Owned by songwriter/publisher. Needed to use the song.
+Using music in film, TV, or commercial requires both licenses.
+
+**Performance rights:** Bars, venues, radio play require license from PROs (ASCAP, BMI, SESAC).
+**Sync license:** Use music in video content (film, TV, ads, games). Negotiated directly with rights holder.
+**Mechanical license:** Reproduce/distribute a song. Compulsory license available at statutory rate in US.
+
+### Film/TV rights
+
+**Option:** Pay to hold rights to a story/script for a period (often 12-18 months) before committing to purchase.
+**Chain of title:** Documented trail of all ownership and license agreements. Essential for financing and distribution.
+**Errors and Omissions (E&O) insurance:** Required by distributors. Protects against copyright, trademark, privacy claims.
+
+## Streaming economics
+
+**Netflix-style SVOD:** Monthly subscriber fee. Content cost = fixed. Marginal viewer = near zero cost.
+**Ad-supported streaming (AVOD):** Free to user; revenue from ads. CPM-based.
+**Transactional (TVOD):** Pay per view/purchase. Digital stores (iTunes, Amazon Prime Video).
+**Window strategy:** Theatrical → PVOD → SVOD/AVOD → linear TV. Windows compressed as streaming dominates.
+
+**Revenue waterfall (film):**
+Box office → Distributor takes 40-50% → Marketing and distribution costs recouped → Participations and residuals → Net profit (often illusory due to creative accounting).
+
+## Digital media and creator economy
+
+**Monetization models:** Ad revenue (CPM/RPM), brand sponsorships, subscriptions (Patreon, Substack), merchandise, events, licensing.
+**YouTube revenue share:** ~55% to creator, 45% to YouTube. $2-10 RPM typical ($2-10 per 1,000 views).
+**Spotify:** ~$0.003-0.005 per stream. 1 million streams ≈ $3,000-5,000.
+**Music on social media:** TikTok, Instagram, YouTube — blanket licenses with labels. Creator doesn't directly earn from music use.
+
+Sources: RIAA (riaa.com — free data), MPAA (motionpictures.org — free), Billboard (billboard.com/free content), Variety/Hollywood Reporter industry news (limited free), Music Business Worldwide (free)

package/skills/industry/industry-nonprofit/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.

package/skills/industry/industry-nonprofit/SKILL.md

@@ -1,77 +1,77 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-nonprofit
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-
-
-
-
-  Nonprofit management — governance, fundraising, grant writing, impact measurement, and nonprofit operations.
-
-
-
-
-
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Nonprofit Management
-
-## Structure and governance
-
-**501(c)(3):** Tax-exempt public charity. Donations are tax-deductible. Cannot engage in political campaigning. Limited lobbying.
-**Board of directors:** Fiduciary responsibility. Strategic oversight. Fundraising. Hire/fire CEO.
-Three duties: Duty of care (informed decisions), Duty of loyalty (no self-dealing), Duty of obedience (mission adherence).
-Best board size: 9-15 members. Mix of skills, networks, and community representation.
-**Executive director/CEO:** Hired by board. Manages staff and operations. Implements strategy.
-**Conflict of interest policy:** Required for 990 reporting. Board members must recuse from decisions where they have personal financial interest.
-
-## Funding landscape
-
-**Individual donors:** 70%+ of all US charitable giving. Major gifts, annual fund, planned giving.
-**Foundations:** Private foundations (require 5% annual payout), community foundations, corporate foundations.
-**Government grants:** Federal, state, local. Often program-specific with compliance requirements.
-**Earned revenue:** Fee-for-service, membership fees, events, social enterprise.
-**Corporate giving:** Cash grants, sponsorships, cause marketing, employee giving/matching.
-
-**Funding mix:** Healthiest nonprofits have diverse revenue streams. Single-source dependency is fragile.
-
-## Fundraising
-
-### Major gifts
-
-Cultivation (relationship building over time) → Solicitation (the ask) → Stewardship (grateful follow-up).
-Prospect research: Capacity (ability to give), Affinity (connection to mission), Propensity (giving history).
-**Moves management:** Track each prospect's progress through cultivation stages.
-**The ask:** Match the ask amount to research. Name the amount. Ask face-to-face when possible. Then be quiet and wait for the answer.
-
-### Grant writing
-
-**Research:** Match your programs to funder's priorities. Read annual reports, 990s, past grants.
-**LOI (Letter of Inquiry):** Often first step. 1-2 pages: organization, program, funding request.
-**Full proposal components:** Executive summary, organizational background, need statement (why is this problem important?), program description (what you'll do), evaluation (how you'll measure success), budget (realistic, narrative justifying each line), organizational capacity.
-**Budget:** Must show: direct program costs, overhead/indirect (typically 10-20%), and demonstrate cost-effectiveness.
-**Grant calendar:** Track deadlines. Allow 4-6 weeks to write quality proposal.
-
-## Financial management
-
-**Restricted vs. unrestricted funds:** Restricted = donor-designated for specific purpose. Must be spent as designated.
-**Form 990:** Annual IRS filing for nonprofits. Public document. Shows financials, governance, compensation.
-**Audit:** Required by most funders above $750K annual revenue. Independent financial audit.
-**Financial ratio watchpoints:**
-Program expense ratio: Program spending / Total spending. Target: 65-75%+.
-Fundraising efficiency: Fundraising cost / Funds raised. Target: < 25%.
-Months of operating reserves: 3-6 months cash on hand recommended.
-
-## Impact measurement
-
-**Logic model:** Inputs → Activities → Outputs → Outcomes → Impact.
-Outputs: What you did (# of people served, classes held). Quantitative, easy to count.
-Outcomes: What changed (% who gained skills, improved health, increased income). Meaningful.
-**Theory of change:** Narrative of how activities lead to outcomes. Assumptions made explicit.
-**Evaluation:** Rigor spectrum: simple tracking → pre/post surveys → comparison group → RCT.
-
-Sources: Nonprofit Finance Fund (nff.org — free), National Council of Nonprofits (councilofnonprofits.org — free), Candid/GuideStar (candid.org — free 990 data), AFP (afpglobal.org — free resources)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-nonprofit
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+
+
+
+
+  Nonprofit management — governance, fundraising, grant writing, impact measurement, and nonprofit operations.
+
+
+
+
+
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Nonprofit Management
+
+## Structure and governance
+
+**501(c)(3):** Tax-exempt public charity. Donations are tax-deductible. Cannot engage in political campaigning. Limited lobbying.
+**Board of directors:** Fiduciary responsibility. Strategic oversight. Fundraising. Hire/fire CEO.
+Three duties: Duty of care (informed decisions), Duty of loyalty (no self-dealing), Duty of obedience (mission adherence).
+Best board size: 9-15 members. Mix of skills, networks, and community representation.
+**Executive director/CEO:** Hired by board. Manages staff and operations. Implements strategy.
+**Conflict of interest policy:** Required for 990 reporting. Board members must recuse from decisions where they have personal financial interest.
+
+## Funding landscape
+
+**Individual donors:** 70%+ of all US charitable giving. Major gifts, annual fund, planned giving.
+**Foundations:** Private foundations (require 5% annual payout), community foundations, corporate foundations.
+**Government grants:** Federal, state, local. Often program-specific with compliance requirements.
+**Earned revenue:** Fee-for-service, membership fees, events, social enterprise.
+**Corporate giving:** Cash grants, sponsorships, cause marketing, employee giving/matching.
+
+**Funding mix:** Healthiest nonprofits have diverse revenue streams. Single-source dependency is fragile.
+
+## Fundraising
+
+### Major gifts
+
+Cultivation (relationship building over time) → Solicitation (the ask) → Stewardship (grateful follow-up).
+Prospect research: Capacity (ability to give), Affinity (connection to mission), Propensity (giving history).
+**Moves management:** Track each prospect's progress through cultivation stages.
+**The ask:** Match the ask amount to research. Name the amount. Ask face-to-face when possible. Then be quiet and wait for the answer.
+
+### Grant writing
+
+**Research:** Match your programs to funder's priorities. Read annual reports, 990s, past grants.
+**LOI (Letter of Inquiry):** Often first step. 1-2 pages: organization, program, funding request.
+**Full proposal components:** Executive summary, organizational background, need statement (why is this problem important?), program description (what you'll do), evaluation (how you'll measure success), budget (realistic, narrative justifying each line), organizational capacity.
+**Budget:** Must show: direct program costs, overhead/indirect (typically 10-20%), and demonstrate cost-effectiveness.
+**Grant calendar:** Track deadlines. Allow 4-6 weeks to write quality proposal.
+
+## Financial management
+
+**Restricted vs. unrestricted funds:** Restricted = donor-designated for specific purpose. Must be spent as designated.
+**Form 990:** Annual IRS filing for nonprofits. Public document. Shows financials, governance, compensation.
+**Audit:** Required by most funders above $750K annual revenue. Independent financial audit.
+**Financial ratio watchpoints:**
+Program expense ratio: Program spending / Total spending. Target: 65-75%+.
+Fundraising efficiency: Fundraising cost / Funds raised. Target: < 25%.
+Months of operating reserves: 3-6 months cash on hand recommended.
+
+## Impact measurement
+
+**Logic model:** Inputs → Activities → Outputs → Outcomes → Impact.
+Outputs: What you did (# of people served, classes held). Quantitative, easy to count.
+Outcomes: What changed (% who gained skills, improved health, increased income). Meaningful.
+**Theory of change:** Narrative of how activities lead to outcomes. Assumptions made explicit.
+**Evaluation:** Rigor spectrum: simple tracking → pre/post surveys → comparison group → RCT.
+
+Sources: Nonprofit Finance Fund (nff.org — free), National Council of Nonprofits (councilofnonprofits.org — free), Candid/GuideStar (candid.org — free 990 data), AFP (afpglobal.org — free resources)

package/skills/industry/industry-pharma/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.

package/skills/industry/industry-pharma/SKILL.md

@@ -1,69 +1,69 @@
----
-watermark: ORIRO
-disable-model-invocation: true
-name: industry-pharma
-provider: ORIRO.ai
-copyright: Copyright (c) 2026 ORIRO.ai
-description: >
-
-
-
-
-
-
-
-
-
-  Pharmaceutical industry — drug development, clinical trials, regulatory pathway, IP, and pharma business model.
-  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
----
-
-# Pharmaceutical Industry
-
-## Drug development process
-
-### Discovery and preclinical (5-10 years)
-
-Target identification: Which biological target (protein, receptor) to address?
-Hit/lead identification: Screen millions of compounds for activity at target.
-Lead optimization: Improve potency, selectivity, safety, and bioavailability.
-Preclinical testing: Animal studies for safety and preliminary efficacy.
-IND (Investigational New Drug) application filed with FDA.
-
-### Clinical trials (6-12 years)
-
-**Phase I:** First in humans. ~20-100 healthy volunteers. Safety, dosing, pharmacokinetics. Success rate: ~70%.
-**Phase II:** Small patient population (~100-500). Preliminary efficacy, optimal dose, safety. Success rate: ~40%.
-**Phase III:** Large randomized controlled trial (~1,000-3,000+ patients). Efficacy vs. standard of care. Success rate: ~65%.
-**Overall Phase I-III success:** Only ~12% of drugs that enter clinical trials make it to approval.
-
-### FDA review
-
-**NDA/BLA submission:** New Drug Application (small molecules) or Biologics License Application (biologics).
-PDUFA date: Review deadline (typically 12 months, 6 months for priority review).
-Advisory committee: External experts advise FDA (non-binding).
-**Priority review, Breakthrough therapy, Accelerated approval, Fast track:** Expedited pathways for serious conditions with unmet needs.
-
-## Key regulatory concepts
-
-**Bioequivalence:** Generic drugs must demonstrate equivalent absorption to brand drug. 80-125% CI on pharmacokinetic parameters.
-**505(b)(2) pathway:** Uses published data/prior approvals for reformulations or new indications.
-**Orphan drug designation:** For diseases affecting < 200,000 US patients. Benefits: 7-year exclusivity, fee waivers, tax credits.
-**Post-market surveillance:** Phase IV studies and safety monitoring after approval.
-
-## Intellectual property
-
-**Patent term:** 20 years from filing date. Effective patent life reduced by development time.
-**Data exclusivity:** Separate from patents. FDA won't approve generics for 5 years (NCE), 3 years (new indication), 12 years (biologics).
-**Patent cliff:** When key patents expire, generic/biosimilar competition can drop prices 80-90%.
-**Evergreening:** Extending patent protection through formulation changes, new indications, pediatric exclusivity.
-
-## Business model
-
-**High-risk, high-reward:** Average R&D cost per approved drug: $1-3 billion. Only 1 in 10,000 screened compounds reaches market.
-**Pricing power:** For novel drugs with no competition and significant clinical benefit, manufacturers have significant pricing power in US market (not in most other countries).
-**US vs. international pricing:** US prices often 3-10× higher than other developed countries due to lack of centralized price negotiation.
-**Generic market:** ~90% of US prescriptions by volume are generics. ~20% by spending.
-**Biosimilars:** Generic equivalents to biologics. More complex, more expensive to develop than small molecule generics.
-
-Sources: FDA (fda.gov — free drug approvals, guidance documents), Drugs@FDA database (free), PhRMA (phrma.org — free industry data), EvaluatePharma (limited free data), STAT News (free healthcare journalism)
+---
+watermark: ORIRO
+disable-model-invocation: true
+name: industry-pharma
+provider: ORIRO.ai
+copyright: Copyright (c) 2026 ORIRO.ai
+description: >
+
+
+
+
+
+
+
+
+
+  Pharmaceutical industry — drug development, clinical trials, regulatory pathway, IP, and pharma business model.
+  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
+---
+
+# Pharmaceutical Industry
+
+## Drug development process
+
+### Discovery and preclinical (5-10 years)
+
+Target identification: Which biological target (protein, receptor) to address?
+Hit/lead identification: Screen millions of compounds for activity at target.
+Lead optimization: Improve potency, selectivity, safety, and bioavailability.
+Preclinical testing: Animal studies for safety and preliminary efficacy.
+IND (Investigational New Drug) application filed with FDA.
+
+### Clinical trials (6-12 years)
+
+**Phase I:** First in humans. ~20-100 healthy volunteers. Safety, dosing, pharmacokinetics. Success rate: ~70%.
+**Phase II:** Small patient population (~100-500). Preliminary efficacy, optimal dose, safety. Success rate: ~40%.
+**Phase III:** Large randomized controlled trial (~1,000-3,000+ patients). Efficacy vs. standard of care. Success rate: ~65%.
+**Overall Phase I-III success:** Only ~12% of drugs that enter clinical trials make it to approval.
+
+### FDA review
+
+**NDA/BLA submission:** New Drug Application (small molecules) or Biologics License Application (biologics).
+PDUFA date: Review deadline (typically 12 months, 6 months for priority review).
+Advisory committee: External experts advise FDA (non-binding).
+**Priority review, Breakthrough therapy, Accelerated approval, Fast track:** Expedited pathways for serious conditions with unmet needs.
+
+## Key regulatory concepts
+
+**Bioequivalence:** Generic drugs must demonstrate equivalent absorption to brand drug. 80-125% CI on pharmacokinetic parameters.
+**505(b)(2) pathway:** Uses published data/prior approvals for reformulations or new indications.
+**Orphan drug designation:** For diseases affecting < 200,000 US patients. Benefits: 7-year exclusivity, fee waivers, tax credits.
+**Post-market surveillance:** Phase IV studies and safety monitoring after approval.
+
+## Intellectual property
+
+**Patent term:** 20 years from filing date. Effective patent life reduced by development time.
+**Data exclusivity:** Separate from patents. FDA won't approve generics for 5 years (NCE), 3 years (new indication), 12 years (biologics).
+**Patent cliff:** When key patents expire, generic/biosimilar competition can drop prices 80-90%.
+**Evergreening:** Extending patent protection through formulation changes, new indications, pediatric exclusivity.
+
+## Business model
+
+**High-risk, high-reward:** Average R&D cost per approved drug: $1-3 billion. Only 1 in 10,000 screened compounds reaches market.
+**Pricing power:** For novel drugs with no competition and significant clinical benefit, manufacturers have significant pricing power in US market (not in most other countries).
+**US vs. international pricing:** US prices often 3-10× higher than other developed countries due to lack of centralized price negotiation.
+**Generic market:** ~90% of US prescriptions by volume are generics. ~20% by spending.
+**Biosimilars:** Generic equivalents to biologics. More complex, more expensive to develop than small molecule generics.
+
+Sources: FDA (fda.gov — free drug approvals, guidance documents), Drugs@FDA database (free), PhRMA (phrma.org — free industry data), EvaluatePharma (limited free data), STAT News (free healthcare journalism)

package/skills/industry/industry-real-estate/LICENSE

@@ -1,21 +1,21 @@
-MIT License
-
-Copyright (c) 2026 ORIRO.ai
-
-Permission is hereby granted, free of charge, to any person obtaining a copy
-of this software and associated documentation files (the "Software"), to deal
-in the Software without restriction, including without limitation the rights
-to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
-copies of the Software, and to permit persons to whom the Software is
-furnished to do so, subject to the following conditions:
-
-The above copyright notice and this permission notice shall be included in all
-copies or substantial portions of the Software.
-
-THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
-IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
-FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
-AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
-LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
-OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
-SOFTWARE.
+MIT License
+
+Copyright (c) 2026 ORIRO.ai
+
+Permission is hereby granted, free of charge, to any person obtaining a copy
+of this software and associated documentation files (the "Software"), to deal
+in the Software without restriction, including without limitation the rights
+to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
+copies of the Software, and to permit persons to whom the Software is
+furnished to do so, subject to the following conditions:
+
+The above copyright notice and this permission notice shall be included in all
+copies or substantial portions of the Software.
+
+THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
+IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
+FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
+AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
+LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
+OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
+SOFTWARE.